Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study

Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study

Background: ICIs have dramatically improved patient outcomes in different malignancies. However, the impact of liver metastases (LM) and number of metastatic sites (MS) remains unclear in patients treated with single-agent anti-PD(L)1. Methods: We aimed to assess the prognostic impact of LM and MS n...

Full description

Bibliographic Details
Main Authors: Madeleine Maugeais, Julien Péron, Stéphane Dalle, Amélie Boespflug, Michaël Duruissaux, Pauline Corbaux, Thibault Reverdy, Gulsum Sahin, Aurélie Rabier, Jonathan Lopez, Nathalie Freymond, Denis Maillet
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Biomedicines
Subjects:
immune checkpoint inhibitors
PD1 inhibitors
PDL1 inhibitors
metastatic sites
liver metastases
prognostic biomarkers
Online Access:https://www.mdpi.com/2227-9059/11/1/83

Internet

https://www.mdpi.com/2227-9059/11/1/83

Similar Items